Purple Biotech (PPBT) Long-Term Investments (2021)

Purple Biotech's (PPBT) quarterly Long-Term Investments came in at $187000.0 in Q4 2021.

Purple Biotech (PPBT) Long-Term Investments (2021) Analysis & Trends

Purple Biotech (PPBT) has 1 years of Long-Term Investments data on file, last reported at $187000.0 in Q4 2021.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $187000.0 in Q4 2021; TTM through Dec 2021 was $187000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $187000.0, changed N/A from the prior year.
Long-Term Investments for Q4 2021 stood at $187000.0.
Over the last five years, Long-Term Investments for PPBT reached as high as $187000.0 in Q4 2021 and fell as low as $187000.0 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Purple Biotech	1.33 Bn	1.33 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	187,000.00